Life Science News
Latest updates from the biotech and pharma world
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera
Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs
Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
Novo Nordisk’s weight loss pill approved by FDA
Novo Nordisk eyes a strong launch with FDA approval of obesity pill
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies
#Novo Nordisk#watched Alzheimer#misses goal#heart health#combat neurodegeneration
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
#Therapeutic Innovations#Forecast Report#Featuring Lonza#Novo Nordisk#Market Therapeutic